自身免疫性疾病 - 多學科復康 / Autoimmune (MRP)

如你有此疾病,請遵照閣下醫生的完整醫療方案;而是否使用多學科復康方案前,你必須咨詢主診醫生的意見,如果閣下的主診醫生不建議您加入補充劑調理組合,請你不要使用。如果你需要尋求其他醫生作第二咨詢,閣下可聯絡我們線上<無邊界醫生>。或你自己城市內的其他專業醫生的再診斷。

自身免疫性疾病

健康的免疫系統保護身體免受疾病和感染。但是如果免疫系統失靈,它會錯誤地攻擊健康的細胞、組織和器官。這些疾病被稱為自身免疫性疾病,可以影響身體的任何部位,削弱身體功能,甚至危及生命。

科學家知道80多種自身免疫性疾病。有些是眾所周知的,如1型糖尿病,多發性硬化症,狼瘡,類風濕關節炎,而其他是罕見的,難以診斷。對於不尋常的自身免疫性疾病,患者在得到正確診斷之前可能要經歷數年的痛苦。這些疾病大多無法治癒。有些需要終生治療來緩解症狀。

這些疾病總共影響了美國2400多萬人。另外800萬人有自身抗體,這種血液分子表明一個人有可能患上自身免疫性疾病。自身免疫疾病正在影響更多的人,原因不明。同樣,這些疾病的病因仍然是個謎。

研究表明,這些疾病可能是遺傳因素和環境因素相互作用的結果。性別、種族和種族特徵與自身免疫性疾病的發生有關。當人們接觸某些環境時,自身免疫性疾病更為常見。

If you have this disease, please follow your doctor's complete medical plan. You must consult the attending doctor before using the multidisciplinary rehabilitation plan. If your attending doctor does not recommend you to join the supplement conditioning combination, please do not use it. If you need to seek second consultation from other doctors, you can contact our online "Doctors Without Borders", or another professional doctor in your own city.

Autoimmune disease

A healthy immune system defends the body against disease and infection. But if the immune system malfunctions, it mistakenly attacks healthy cells, tissues, and organs. Called autoimmune disease, these attacks can affect any part of the body, weakening bodily function and even turning life-threatening.

Scientists know about more than 80 autoimmune diseases. Some are well known, such as type 1 diabetes, multiple sclerosis, lupus, and rheumatoid arthritis, while others are rare and difficult to diagnose. With unusual autoimmune diseases, patients may suffer years before getting a proper diagnosis. Most of these diseases have no cure. Some require lifelong treatment to ease symptoms.

Collectively, these diseases affect more than 24 million people in the United States. An additional eight million people have auto-antibodies, blood molecules that indicate a person’s chance of developing autoimmune disease. Autoimmune diseases are affecting more people for reasons unknown. Likewise, the causes of these diseases remain a mystery.

Studies indicate these diseases likely result from interactions between genetic and environmental factors. Gender, race, and ethnicity characteristics are linked to a likelihood of developing an autoimmune disease. Autoimmune diseases are more common when people are in contact with certain environmental exposures.

Ref: https://www.niehs.nih.gov/health/topics/conditions...


  1. Horvath A, Alvarado F, Szocs J, et al. Metabolic Effects of calagualine, an antitumoral saponine of Polypodium leucotomos. Nature. 1967; 214:1256-1258.
  2. Padilla HC, Lainez H, Pacheco JA. A new agent (hydrophilic fraction of Polypodium leucotomos) for management of psoriasis. Int J Dermatol. 1974; 13:276-282.
  3. Ruiz H. Disertaciones sobre la raiz de la Rathania, de la Calaguala y de la China y acerca de la yerba llamada Canchalagua. Madrid: Fundacion Ciencias de la Salud, Sociedad Estatal Quinto Centenario y Real Jardin Botanico (CISC); 1992. Cited by: Gonzalez S, Alonso-Lebrero JL, Del Rio R, et al. Polypodium Leucotomos Extract: A Nutraceutical with Photoprotective Properties. Drugs Today. 2007; 43(7):475-485.
  4. Runger TM. Ultraviolet Light. In: Bolognia JL, Jorizzo JL, Schaffer JV, eds. Dermatology. Vol 2. 3rd ed. Philadelphia, PA: Elsevier; 2012:1455-1465.
  5. Garcia F, Pivel JP, Guerrero A, et al. Phenolic components and antioxidant activity of Fernblock, an aqueous extract of the aerial parts of the fern Polypodium leucotomos. Methods Find Exp Clin Pharmacol. 2006; 28: 157-160.
  6. Gombau L, Garcia F, Lahoz A, et al. Polypodium leucotomos extract: Antioxidant activity and disposition. Toxicol In Vitro. 2006; 20: 464-471.
  7. Gonzalez S, Alcaraz MV, Cuevas J, et al. An Extract of the Fern Polypodium Leucotomos (Difur) modulates Th1/Th2 Cytokines Balance in Vitro and Appears to Exhibit Anti-angiogenic Activities in Vivo:Pathogenic Relationships and Therapeutic Implications. Anticancer Res. 2000; 20:1567-1576.
  8. Alonso-Lebrero JL, Dominguez-Jimenez C, Tejedor R, et al. Photoprotective properties of a hydrophilic extract of the fern Polypodium leucotomos on human skin cells. J Photochem Photobiol, B. 2003; 70:31-37.
  9. Philips N, Smith J, Keller T, et al. Predominant effects of Polypodium leucotomos on membrane integrity, lipid peroxidation, and expression of elastin and matrixmetalloproteinase-1 in ultraviolet radiation exposed fibroblasts, and keratinocytes. J Dermatol Sci. 2003; 32:1-9.
  10. Capote R, Alonso-Lebrero JL, Garcia F, et al. Polypodium leucotomos extract inhibits trans-urocanic acid photoisomerization and photodecomposition. J Photochem Photobiol, B. 2006; 82:173-179.
  11. Middelkamp-Hup MA, Pathak MA, Parrado C, et al. Oral Polypodium leucotomos extract decreases ultraviolet-induced damage of human skin. J Am Acad Dermatol. 2004; 51(6): 910-918.
  12. Villa A, Viera MH, Amini S, et al. Decrease of ultraviolet A light–induced “common deletion” in healthy volunteers after oral Polypodium leucotomos extract supplement in a randomized clinical trial. J Am Acad Dermatol. 2010; 62(3): 511-513.
  13. Berneburg M, Plettenburg H, Medve-König K, et al. Induction of the photoaging- associated mitochondrial common deletion in vivo in normal human skin. J Invest Dermatol. 2004; 122:1277-1283.
  14. Zattra E, Coleman C, Arad S, et al. Oral Polypodium leucotomos decreases UV-induced Cox-2 expression, inflammation, and enhances DNA repair in Xpc +/- mice. Am J Pathol. 2009; 175:1952-1961.
  15. Aguilera P, Carrera C, Puig-Butille JA, et al. Benefits of oral Polypodium Leucotomos extract in MM high-risk patients. J Eur Acad Dermatol Venereol. 2013; 27:1095-1100.
  16. Caccialanza M, Percivalle S, Piccinno R, Brambilla R. Photoprotective activity of oral polypodium leucotomos extract in 25 patients with idiopathic photodermatoses. Photodermatol Photoimmunol Photomed. 2007; 23:46-47.
  17. Caccialanza M, Recalcati S, Piccinno R. Oral polypodium leucotomos extract photoprotective activity in 57 patients with idiopathic photodermatoses. G Ital Dermatol Venereol. 2011; 146: 85-87.
  18. Tanew A, Radakovic S, Gonzalez S, et al. Oral administration of a hydrophilic extract of Polypodium leucotomos for the prevention of polymorphic light eruption. J Am Acad Dermatol. 2012; 66(1):58-62.
  19. Breithaupt AD, Jacob SE. Subacute Cutaneous Lupus Erythematosus: A Case Report of Polypodium leucotomos as an Adjuvant Therapy. Cutis. 2012;89:183-184.
  20. Martin LK, Caperton C, Woolery-Lloyd H, Avashia N. A randomized doubleblind placebo controlled study evaluating the effectiveness and tolerability of oral Polypodium leucotomos in patients with melasma. Poster #4630. Paper presented at: American Academy of Dermatology; March 2012; San Diego, CA.
  21. Ahmed A, Lopez I, Perese F, et al. A Randomized, Double-Blinded, Placebo- Controlled Trial of Oral Polypodium Leucotomos Extract as Adjunct to Sunscreen in the Treatment of Melasma. JAMA Dermatol. 2013;1-2. doi:10.1001/ jamadermatol.2013.4294.
  22. Pacifico A, Iacovelli P, Paro Vidolin A, Leone G. Combined treatment of NBUVB phototherapy and oral Polypodium Leucotomos extract versus NBUVB therapy alone in the treatment of patients with vitiligo. Poster #3111. Paper presented at: American Academy of Dermatology; March 2009; San Francisco, CA.
  23. Reyes E, Jaén P, Cuevas J, et al. Systemic immunomodulatory effects of Polypodium leucotomos as an adjuvant to PUVA therapy in generalized vitiligo: A pilot study. J Dermatol Sci. 2006; 41(3):213-216.
  24. Middlekamp MA, Bos JD, Ruis-Diaz F, et al. Treatment of vitiligo vulgaris with narrow-band UVB and oral Polypodium leucotomos extract: a randomized double-blind placebo-controlled study. J Eur Acad Dermatol Venereol. 2007; 21(7):942-950.
  25. De las Heras ME, Ledo E, Gonzalez S, et al. Polypodium leucotomos extract as adjuvant to PUVA therapy in the treatment of Plaque Psoriasis. Med Cutan Iber Lat Am. 1997; 25:103-107.
  26. Middlekamp-Hup MA, Pathak MA, Parrado C, et al. Orally administered Polypodium leucotomos extract decreases psoralen-UVA-induced phototoxicity, pigmentation, and damage of human skin. J Am Acad Dermatol. 2004; 50:41-49.
  27. Ramirez-Bosca A, Zapater P, Betlloch I, et al. Polypodium leucotomos Extract in Atopic Dermatitis: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. Actas Dermosifiliogr. 2012; 103:599-607.
  28. Solivellas BM, Martin TC. Polypodium leucotomos Extract use to prevent and reduce the risk of infectious diseases in high performance athletes. Infect Drug Resist. 2012; 5:149-153.
  29. Bernd A, Ramirez-Bosca A, Huber H, et al. In vitro studies on the immunomodulating effects of Polypodium leucotomos extract on human leucocyte fractions. Arzneimittelforschung. 1995; 45(2): 901-904.
  30. Sempere JM, Campos A, Rodrigo C, et al. Induction of T lymphocytes and NK cells by anapsos. Inmunologia. 1999; 18(Suppl 1)

Featured Products